Thu, Aug 1, 8:38 PM (88 days ago)
Becton, Dickinson and Company (BD) reported Q3 2024 revenues of $4.990 billion, a 2.3% increase from Q3 2023. Key drivers included strong sales in the Medication Delivery Solutions and Medication Management Solutions units, offset by unfavorable market dynamics in China. The Life Sciences segment saw growth in Integrated Diagnostic Solutions, while the Interventional segment benefited from strong sales in Urology and Critical Care. Gross profit margin improved to 46.2% from 43.1%, aided by lower manufacturing costs and favorable product mix. Operating income increased, reflecting cost containment and productivity initiatives. Net income rose to $487 million, with diluted EPS at $1.68. Cash flow from operations was $2.666 billion for the first nine months of 2024. BD announced a $4.2 billion acquisition of Edwards Lifesciences' Critical Care product group, expected to close by year-end 2024, funded by recent debt issuances. The company faces ongoing regulatory and legal challenges, including FDA and environmental compliance issues.